Idiopathic pulmonary fibrosis is a devastating disorder characterized by the progressive thickening and stiffening of lung tissue through abnormal fibroblast activity, which obliterates the delicate alveolar architecture necessary for efficient gas exchange. Until now, the molecular underpinnings steering macrophage behavior and their communication with fibroblasts remained incomplete, thereby limiting targeted therapies. The current study meticulously dissects the crosstalk between epigenetic regulation and mitochondrial homeostasis in macrophages, revealing how Hdac11 suppression of the Parkin protein disrupts mitophagy pathways. This impairment fuels an inflammatory and fibrotic milieu through macrophage skewing toward a pro-fibrotic M2 phenotype.

Histone deacetylases like Hdac11 belong to an enzyme family pivotal in modulating chromatin structure and gene expression by removing acetyl groups from histone proteins, thereby tightening DNA packaging and repressing gene transcription. Unlike classical Hdacs more widely studied in cancer and neurological disorders, Hdac11 has remained relatively enigmatic until now. The researchers demonstrate how Hdac11 specifically downregulates Parkin, an E3 ubiquitin ligase central to selectively removing damaged mitochondria via mitophagy. The resulting mitochondrial dysfunction promotes macrophage alternative activation, a state linked to tissue repair but also pathological fibrosis when chronically engaged.

Mitochondria, often dubbed the cell’s powerhouses, constantly face oxidative stress and potential damage, necessitating stringent quality control mechanisms such as mitophagy to maintain cellular homeostasis and function. Parkin-mediated mitophagy removes defective mitochondria, preventing the release of pro-inflammatory signals and limiting fibrogenic cascades. The novel findings illuminate how Hdac11-mediated repression of Parkin stymies this essential cleanup operation, precipitating an accumulation of dysfunctional mitochondria that skew macrophages toward an M2-type immune phenotype. This macrophage polarization fosters secretion of fibrogenic cytokines and growth factors, which in turn activate resident fibroblasts.

Notably, the study integrates in vitro cellular models with in vivo murine fibrosis models, allowing for a multi-layered understanding of Hdac11’s role in disease pathogenesis. Silencing Hdac11 expression revived Parkin-dependent mitophagy and reversed the fibrotic phenotype, substantially reducing myofibroblast accumulation and pulmonary fibrosis severity. Conversely, Hdac11 overexpression exacerbated lung fibrosis, underscoring its critical involvement. These functional validations highlight Hdac11 as a promising therapeutic target capable of interrupting the vicious cycle of macrophage-driven fibrogenesis.

The implications of this research extend beyond idiopathic pulmonary fibrosis, potentially influencing our understanding of fibrotic disorders across multiple organ systems where macrophage plasticity and mitochondrial dysfunction are similarly implicated. Epigenetic regulators like Hdac11 may represent a universal nodal point integrating environmental cues, immune cell state, and mitochondrial quality to dictate tissue remodeling outcomes. Targeting Hdac11 could thus offer a strategy not only for pulmonary fibrosis but also for cardiac, hepatic, and renal fibrosis—all conditions where myofibroblast-mediated scarring compromises organ function.

The authors also delve into mechanistic details elucidating how Hdac11 interacts with the Parkin promoter, impacting its transcriptional activation. Chromatin immunoprecipitation assays revealed Hdac11’s recruitment to specific regulatory regions of the Parkin gene, suppressing its expression via histone deacetylation. This epigenetic repression translates into diminished Parkin protein abundance, impeding mitophagic flux. Such mechanistic insights offer opportunities for designing small molecules or genetic tools capable of disentangling this interaction to restore mitochondrial quality control in fibrotic macrophages.

Furthermore, the research team evaluated the tissue localization and expression patterns of Hdac11 and Parkin in lung biopsies from IPF patients, confirming their inverse correlation and supporting translational relevance. Immunohistochemical analysis showed prominent Hdac11 expression within macrophage populations in fibrotic regions coinciding with suppressed Parkin levels, correlating with increased myofibroblast markers. These human data validate findings obtained from animal models and underscore the clinical potential of modulating the Hdac11-Parkin axis.

Mitophagy impairment has long been recognized as a contributor to chronic lung diseases, yet the regulatory nodes controlling this process have remained elusive. By identifying Hdac11 as a novel epigenetic brake on mitophagy, this study generates a paradigm shift in mitophagy-related fibrosis research. It prompts re-examination of how metabolic stress, epigenetics, and immune plasticity intersect to propagate fibrogenesis. Moreover, this refinement of fibrotic pathophysiology can guide precision medicine approaches that tailor treatment based on molecular subtypes of macrophage dysregulation.

Importantly, the study clarifies the dual role of macrophages in lung homeostasis and disease. While M1 macrophages classically promote inflammation and pathogen clearance, M2 macrophages are associated with immunosuppression and tissue repair. Dysfunctionally sustained M2 polarization, as orchestrated by Hdac11 via mitophagy inhibition, underlies maladaptive fibrotic remodeling rather than healing. This distinction is critical for therapeutic development since broadly suppressing macrophages risks impairing host defense, whereas modulating epigenetic and mitochondrial pathways offers specificity and reduces collateral damage.

The clinical portfolio for pulmonary fibrosis has expanded modestly in recent years with antifibrotic drugs such as pirfenidone and nintedanib, yet these agents slow but do not halt disease progression and come with substantial side effects. The elucidation of Hdac11’s role provides fresh opportunities for developing next-generation therapies that target the cellular and molecular origins of fibrosis. Epigenetic inhibitors or mitophagy enhancers could restore macrophage function and dampen fibrotic signaling with potentially improved efficacy and tolerability.

As the global burden of fibrotic lung diseases rises and survival remains dismal, this research injects renewed optimism. The integration of mitochondrial biology, epigenetics, and immunology as demonstrated here will likely inform future clinical trials and biomarker discovery efforts. Therapeutic manipulation of Hdac11 will demand rigorous preclinical testing to evaluate off-target effects given its nuclear functions, but the potential rewards are monumental—transforming the grim prognosis of IPF into manageable or even reversible fibrosis.

In conclusion, the seminal work led by Nie, Xu, and Liu marks a turning point in pulmonary fibrosis research by linking Hdac11-mediated suppression of Parkin-dependent mitophagy to macrophage M2-type polarization and myofibroblast proliferation. Their insights deepen our molecular understanding of fibrosis and open new therapeutic frontiers centered on epigenetic modulation and mitochondrial quality control. The scientific and medical communities eagerly await the translation of these findings into clinical strategies that can ultimately alleviate the suffering of individuals afflicted by this relentless lung disease.

Subject of Research: The role of Hdac11 in promoting idiopathic pulmonary fibrosis via macrophage M2-type polarization and myofibroblast accumulation through inhibition of Parkin-dependent mitophagy.

Article Title: Hdac11 promotes idiopathic pulmonary fibrosis through macrophage M2-type polarization and myofibroblast accumulation by inhibiting Parkin-dependent mitophagy.

Article References: Nie, Y., Xu, L., Liu, Y. et al. Hdac11 promotes idiopathic pulmonary fibrosis through macrophage M2-type polarization and myofibroblast accumulation by inhibiting Parkin-dependent mitophagy. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71639-x

Image Credits: AI Generated

m6A methylation involves the addition of a methyl group to the nitrogen-6 position of adenosine residues within RNA molecules, modulating RNA metabolism including translation, splicing, stability, and nuclear export. This reversible modification is orchestrated by three classes of proteins: writers, erasers, and readers. Writers such as methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) deposit the methyl mark; erasers including fat mass and obesity-associated protein (FTO) and AlkB homolog 5 (ALKBH5) remove it; while readers like YTH domain family proteins and insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) decode the m6A signal to influence downstream RNA fate. Each component plays a unique and critical role in the pathogenesis of ALI, offering a wealth of therapeutic targets.

Among the m6A writers, METTL3 has emerged as a central mediator exacerbating lung injury. Experimental evidence reveals that METTL3 modifies key messenger RNAs (mRNAs) and non-coding RNAs, thereby enhancing alveolar epithelial cell apoptosis, inflammatory cytokine production, and pyroptotic cell death—a highly inflammatory form of programmed cell demise. Remarkably, downregulation of METTL3 attenuates these damaging processes, highlighting its potential as a molecular switch in controlling ALI severity.

Similarly, METTL14 deficiency dampens the inflammatory milieu within the lungs by significantly reducing pro-inflammatory cytokines and inhibiting activation of inflammasomes—multiprotein complexes crucial for innate immune responses. By limiting inflammasome activity, METTL14 knockdown diminishes pulmonary edema and tissue injury, conveying protective effects in experimental ALI models. This showcases how manipulating m6A writer activity can recalibrate harmful inflammatory cascades in lung tissue.

Another writer, METTL4, although less studied, has been implicated in ferroptosis—a regulated, iron-dependent form of cell death increasingly recognized in ALI pathology. METTL4 deletion downregulates ferroptosis-related markers in alveolar epithelial cells, alleviating cellular demise and lung damage. The emerging link between m6A methylation and ferroptosis introduces an additional layer of complexity to the molecular regulation of ALI.

On the flip side, m6A erasers dictate the removal of methyl marks, balancing the epigenetic landscape. FTO knockout experiments demonstrate alleviation of alveolar structural disruption and pulmonary inflammation, indicating that FTO activity exacerbates tissue injury. Intriguingly, elevated FTO levels impair microRNA function, thereby amplifying inflammatory signaling and macrophage responses, particularly in obese murine models. This positions FTO as a dual-edged player whose modulation may have therapeutic implications tailored to patient metabolic status.

ALKBH5, another m6A demethylase, fosters ferroptosis via stabilization of a circular RNA, revealing an unanticipated mechanism by which RNA modifications influence cell death pathways in ALI. This highlights the versatility of m6A regulation beyond linear RNAs, expanding the landscape of epigenetic control and its repercussions on pulmonary injury dynamics.

m6A readers decode methylation marks and dictate transcript fate. YTHDF1 impacts mitochondrial function and promotes polarization of macrophages to the pro-inflammatory M1 phenotype, thereby worsening tissue inflammation. Its role underscores how m6A reader activity integrates metabolic and immune responses during lung injury, reinforcing the concept of epitranscriptional regulation as a nexus of cellular crosstalk.

IGF2BP3, another reader with increased expression in lung tissue from patients suffering acute respiratory distress syndrome, signifies the human relevance of these molecular findings. Its elevated presence connects m6A reader activity with clinical disease severity, prompting further investigations into patient stratification and biomarker development based on m6A-related protein profiles.

Despite these advances, the review notes contradictory results in m6A research pertaining to ALI. Such discrepancies arise from factors including the dynamic and time-dependent nature of m6A methylation, variability in expression of m6A-related proteins across distinct lung cell populations, and heterogeneity in ALI modeling methods—from intraperitoneal lipopolysaccharide (LPS) injections to cecal ligation and puncture (CLP) surgeries. This variability emphasizes the need for standardized experimental protocols and logistically sound time-point analyses to resolve conflicting data.

Looking forward, translating these mechanistic insights into clinical validation remains paramount. Currently, most data derive from animal models; rigorous human clinical studies are necessary to confirm the role of m6A modifications in ALI pathophysiology. Additionally, dissecting cell-type-specific m6A regulation and unraveling intercellular signaling networks within the injured lung microenvironment will enhance understanding of tissue-specific epigenetic landscapes.

Integration of multiomics technologies coupled with advanced nanodelivery systems promises to revolutionize ALI treatment paradigms. Such approaches may enable precise targeting of m6A-modulatory proteins, facilitating the development of novel precision medicines tailored to individual molecular signatures. Ultimately, this synergistic strategy could significantly improve prognosis in patients suffering from acute lung injury and related syndromes.

This groundbreaking review authored by Professor Fangwei Li and Dr. Yating Hu represents a seminal step in delineating the multifaceted roles of m6A methylation in ALI. By bridging molecular biology with translational medicine, it lays a robust foundation for future research and therapeutic innovation poised to transform critical respiratory care.

Subject of Research: Not applicable

Article Title: N6-methyladenosine methylation in acute lung injury: Mechanisms and research progress

News Publication Date: 20-Aug-2025

Web References: Not provided

References: DOI: 10.1016/j.jointm.2025.07.001

Image Credits: Anjanettew